Geode Capital Management LLC Increases Holdings in Tenaya Therapeutics, Inc. (NASDAQ:TNYA)

Geode Capital Management LLC boosted its holdings in shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) by 5.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,296,156 shares of the company’s stock after purchasing an additional 66,968 shares during the period. Geode Capital Management LLC owned about 1.64% of Tenaya Therapeutics worth $2,502,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in TNYA. Bank of New York Mellon Corp grew its holdings in shares of Tenaya Therapeutics by 12.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 237,597 shares of the company’s stock worth $737,000 after acquiring an additional 26,103 shares during the period. Rhumbline Advisers grew its holdings in shares of Tenaya Therapeutics by 10.5% during the 2nd quarter. Rhumbline Advisers now owns 78,160 shares of the company’s stock worth $242,000 after acquiring an additional 7,441 shares during the period. American Century Companies Inc. grew its holdings in shares of Tenaya Therapeutics by 27.7% during the 2nd quarter. American Century Companies Inc. now owns 102,114 shares of the company’s stock worth $317,000 after acquiring an additional 22,146 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of Tenaya Therapeutics by 42.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 102,026 shares of the company’s stock worth $316,000 after acquiring an additional 30,446 shares during the period. Finally, Renaissance Technologies LLC grew its holdings in shares of Tenaya Therapeutics by 144.1% during the 2nd quarter. Renaissance Technologies LLC now owns 157,460 shares of the company’s stock worth $488,000 after acquiring an additional 92,960 shares during the period. Hedge funds and other institutional investors own 90.54% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on TNYA. Chardan Capital reiterated a “buy” rating and set a $18.00 target price on shares of Tenaya Therapeutics in a report on Wednesday, December 18th. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price objective on shares of Tenaya Therapeutics in a research report on Wednesday, December 18th. Leerink Partners reaffirmed an “outperform” rating on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $16.00 price objective on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $17.33.

Tenaya Therapeutics Trading Down 2.0 %

Shares of TNYA opened at $1.49 on Wednesday. The business’s fifty day simple moving average is $2.34 and its two-hundred day simple moving average is $2.51. Tenaya Therapeutics, Inc. has a 12 month low of $0.99 and a 12 month high of $7.01. The company has a market cap of $118.04 million, a price-to-earnings ratio of -1.03 and a beta of 2.89.

Tenaya Therapeutics (NASDAQ:TNYA) last issued its earnings results on Wednesday, November 6th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.07. As a group, research analysts forecast that Tenaya Therapeutics, Inc. will post -1.35 EPS for the current year.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.